These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

740 related items for PubMed ID: 17728218

  • 21. hK2 and free PSA, a prognostic combination in predicting minimal prostate cancer in screen-detected men within the PSA range 4-10 ng/ml.
    Raaijmakers R, de Vries SH, Blijenberg BG, Wildhagen MF, Postma R, Bangma CH, Darte C, Schröder FH.
    Eur Urol; 2007 Nov; 52(5):1358-64. PubMed ID: 17499425
    [Abstract] [Full Text] [Related]

  • 22. Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma.
    Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG.
    Cancer; 2004 Apr 01; 100(7):1397-405. PubMed ID: 15042673
    [Abstract] [Full Text] [Related]

  • 23.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 24. Tumor characteristics in a population-based prostate cancer screening trial with prostate-specific antigen.
    Mäkinen T, Tammela TL, Hakama M, Stenman UH, Rannikko S, Aro J, Juusela H, Määttänen L, Auvinen A.
    Clin Cancer Res; 2003 Jul 01; 9(7):2435-9. PubMed ID: 12855615
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Potentially advanced malignancies detected by screening for prostate carcinoma after an interval of 4 years.
    Postma R, Roobol M, Schröder FH, van der Kwast TH.
    Cancer; 2004 Mar 01; 100(5):968-75. PubMed ID: 14983492
    [Abstract] [Full Text] [Related]

  • 27. Prostate specific antigen testing and digital rectal examination before and during a randomized trial of screening for prostate cancer: European randomized study of screening for prostate cancer, Rotterdam.
    Beemsterboer PM, de Koning HJ, Kranse R, Trienekens PH, van der Maas PJ, Schröder FH.
    J Urol; 2000 Oct 01; 164(4):1216-20. PubMed ID: 10992369
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. A comparison of first and repeat (four years later) prostate cancer screening in a randomized cohort of a symptomatic men aged 55-75 years using a biopsy indication of 3.0 ng/ml (results of ERSPC, Rotterdam).
    Roobol MJ, Schröder FH, Kranse R, ERSPC, Rotterdam.
    Prostate; 2006 May 01; 66(6):604-12. PubMed ID: 16388508
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Prostate-specific antigen-based serial screening may decrease prostate cancer-specific mortality.
    Efstathiou JA, Chen MH, Catalona WJ, McLeod DG, Carroll PR, Moul JW, Roehl KA, D'Amico AV.
    Urology; 2006 Aug 01; 68(2):342-7. PubMed ID: 16904449
    [Abstract] [Full Text] [Related]

  • 33. Prostate specific antigen based biennial screening is sufficient to detect almost all prostate cancers while still curable.
    Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG, Pileblad E.
    J Urol; 2003 May 01; 169(5):1720-3. PubMed ID: 12686817
    [Abstract] [Full Text] [Related]

  • 34. Predictors of biological aggressiveness of prostate specific antigen screening detected prostate cancer.
    Isola J, Auvinen A, Poutiainen M, Kakkola L, Järvinen TA, Määttänen L, Stenman UH, Tammela T, Hakama M, Visakorpi T.
    J Urol; 2001 May 01; 165(5):1569-74. PubMed ID: 11342919
    [Abstract] [Full Text] [Related]

  • 35. Prostate cancer risk assessment program: a 10-year update of cancer detection.
    Giri VN, Beebe-Dimmer J, Buyyounouski M, Konski A, Feigenberg SJ, Uzzo RG, Hanks G, Godwin AK, Chen DY, Gordon R, Cescon T, Raysor S, Watkins-Bruner D.
    J Urol; 2007 Nov 01; 178(5):1920-4; discussion 1924. PubMed ID: 17868726
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Non-systematic screening for prostate cancer in Sweden--survey from the National Prostate Cancer Registry.
    Stattin P, Johansson R, Damber JE, Hellström M, Hugosson J, Lundgren R, Varenhorst E, Johansson JE.
    Scand J Urol Nephrol; 2003 Nov 01; 37(6):461-5. PubMed ID: 14675917
    [Abstract] [Full Text] [Related]

  • 40. Prostate cancer incidence and disease-specific survival of men with initial prostate-specific antigen less than 3.0 ng/ml who are participating in ERSPC Rotterdam.
    Bul M, van Leeuwen PJ, Zhu X, Schröder FH, Roobol MJ.
    Eur Urol; 2011 Apr 01; 59(4):498-505. PubMed ID: 21334136
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 37.